- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04984798
Vitamin E Efficacy in HI/HA
Efficacy of Vitamin E in Hyperinsulinism/Hyperammonemia Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to determine an effective dose of vitamin E to reduce protein-induced hyperinsulinemia in subjects with HI/HA syndrome. Secondary objectives are to assess the effects of vitamin E on plasma C-peptide concentrations, serum alpha-tocopherol concentrations, blood ammonia concentrations, hypoglycemic events, and seizure frequency. The effect of vitamin E on brain glutamate levels and electroencephalogram findings will be explored.
This single-group open-label dose-finding clinical study will use a before-and-after design to compare clinical and laboratory data before and after 2-3 weeks of escalating doses of oral vitamin E treatment in subjects with HI/HA syndrome.
This single-site outpatient study will recruit up to 5 adult participants (18 years of age or older) with HI/HA syndrome.
Each study visit will consist of blood tests, an IV leucine acute insulin response (AIR) test, home glucose meter and continuous glucose monitor (CGM) review, and a symptom questionnaire. The baseline and final visits will also include electroencephalogram (EEG) and brain magnetic resonance imaging (MRI) with glutamate chemical exchange saturation transfer (GluCEST) analysis. After baseline assessments, including a 2 week run-in period of CGM use, subjects will take twice daily oral vitamin E (alpha-tocopherol) at home. After steady-state of that dose of vitamin E has been achieved (i.e. at least 2 weeks on the dose of vitamin E), subjects will return for the next study visit. If there is no dose-limiting toxicity, then the twice daily vitamin E dose will be increased, and the subjects will return for a subsequent study visit after at least 2 weeks. If there is no dose-limiting toxicity at this visit, then the twice daily vitamin E dose will be increased again, and the subjects will return for a final study visit after at least 2 weeks. If toxicity is identified at any point, vitamin E will be discontinued and final study visit procedures will be performed.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females age ≥18 years.
- Diagnosis of HI/HA syndrome (based on glutamate dehydrogenase 1 [GLUD1] genetic test result and/or history of diazoxide-responsive hyperinsulinism with persistently elevated blood ammonia concentrations).
- Able to swallow softgels.
- Informed consent.
Exclusion Criteria:
- Vitamin E supplementation within 30 days prior to enrollment, including multivitamins containing vitamin E.
- Individuals who have experienced an allergic reaction to vitamin E.
- On concurrent therapy with a medication known to adversely interact with vitamin E.
- On concurrent therapy with a medication, supplement, or herbal remedy known to increase bleeding risk, including antiplatelet or anticoagulation therapy.
- Known increased risk of bleeding (coagulopathy, hemophilia, platelet defect, or platelet disorder) based on history, known or suspected vitamin K deficiency, baseline international normalized ratio (INR) >1.5, baseline prothrombin time (PT) >1.5 times the upper limit of normal, baseline partial thromboplastin time (PTT) >1.5 times the upper limit of normal, or baseline abnormal platelet function test result (VerifyNow-Aspirin <550 aspirin reactivity units [ARU], VerifyNow-adenosine diphosphate [ADP]/PRU <180 P2Y12 reaction units [PRU]).
- Known clotting disorder, including prior episodes of deep vein thrombosis or pulmonary embolism within the past 6 months.
- Evidence of severe hematologic abnormality including severe anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelet count <150,000/mm3).
- Abnormal score on International Society on Thrombosis and Haemostasis (ISTH)-Bleeding Assessment Tool (>4 if male; >5 if female).
- Planned elective surgical procedure during study period.
- Evidence of a medical condition that might alter results or compromise the interpretation of results, including active infection, kidney failure, severe liver dysfunction, severe respiratory or cardiac failure.
- Any investigational drug use within 30 days prior to enrollment.
- Current use of somatostatin analog.
- Current adherence to a ketogenic diet.
- Pregnant or lactating females. Females must have a negative urine pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study and a minimum of 2 weeks after the last dose of study drug.
- Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
- Unable to provide informed consent (e.g. impaired cognition or judgment).
- Limited English proficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin E Dose-Escalation
Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks.
The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily).
Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
|
Twice daily oral supplementation with Vitamin E for 6-9 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
protein-induced hyperinsulinemia
Time Frame: 4-11 weeks
|
Change in plasma insulin concentration area under the curve (AUC) during leucine AIR test after vitamin E treatment compared to before.
|
4-11 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mean glucose concentration
Time Frame: 4-11 weeks
|
Change in mean glucose concentration detected on continuous glucose monitor (CGM) during the study interval after vitamin E treatment compared to before.
|
4-11 weeks
|
proportion of time spent with glucose <70 mg/dL
Time Frame: 4-11 weeks
|
Change in proportion of time spent with glucose <70 mg/dL, detected on continuous glucose monitor (CGM) during the study interval after vitamin E treatment compared to before.
|
4-11 weeks
|
proportion of time spent with glucose <50 mg/dL
Time Frame: 4-11 weeks
|
Change in proportion of time spent with glucose <50 mg/dL, detected on continuous glucose monitor (CGM) during the study interval after vitamin E treatment compared to before.
|
4-11 weeks
|
hypoglycemic episodes
Time Frame: 4-11 weeks
|
Change in frequency of hypoglycemic episodes (plasma glucose <70 mg/dL and plasma glucose <50 mg/dL) detected on home glucose meter and/or continuous glucose monitor (CGM) after vitamin E treatment compared to before.
|
4-11 weeks
|
protein-induced C-peptide release
Time Frame: 4-11 weeks
|
Change in plasma C-peptide concentration area under the curve (AUC) during leucine AIR test after vitamin E treatment compared to before.
|
4-11 weeks
|
vitamin E
Time Frame: 4-11 weeks
|
Change in serum alpha-tocopherol concentration after vitamin E treatment compared to before.
|
4-11 weeks
|
ammonia
Time Frame: 4-11 weeks
|
Change in blood ammonia concentration after vitamin E treatment compared to before.
|
4-11 weeks
|
seizures
Time Frame: 4-11 weeks
|
Change in frequency of seizures, based on symptom questionnaire, after vitamin E treatment compared to before.
|
4-11 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of participants with EEG abnormalities
Time Frame: 8-11 weeks
|
Change in brain electrical activity after vitamin E treatment compared to before.
|
8-11 weeks
|
brain glutamate
Time Frame: 8-11 weeks
|
Change in glutamate concentration, as measured by brain GluCEST percent contrast, after vitamin E treatment compared to before.
|
8-11 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elizabeth A Rosenfeld, MD, Children's Hospital of Philadelphia
Publications and helpful links
General Publications
- Palladino AA, Stanley CA. The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord. 2010 Sep;11(3):171-8. doi: 10.1007/s11154-010-9146-0.
- Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N, Ganapathy K, Bhatti T, Stanley CA, Ganguly A. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013 Feb;98(2):E355-63. doi: 10.1210/jc.2012-2169. Epub 2012 Dec 28.
- Hsu BY, Kelly A, Thornton PS, Greenberg CR, Dilling LA, Stanley CA. Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. J Pediatr. 2001 Mar;138(3):383-9. doi: 10.1067/mpd.2001.111818.
- Stanley CA, Baker L. Hyperinsulinism in infancy: diagnosis by demonstration of abnormal response to fasting hypoglycemia. Pediatrics. 1976 May;57(5):702-11.
- Li M, Smith CJ, Walker MT, Smith TJ. Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000. doi: 10.1074/jbc.M109.020222. Epub 2009 Jun 15.
- Ferslew KE, Acuff RV, Daigneault EA, Woolley TW, Stanton PE Jr. Pharmacokinetics and bioavailability of the RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration. J Clin Pharmacol. 1993 Jan;33(1):84-8. doi: 10.1002/j.1552-4604.1993.tb03909.x.
- Treberg JR, Clow KA, Greene KA, Brosnan ME, Brosnan JT. Systemic activation of glutamate dehydrogenase increases renal ammoniagenesis: implications for the hyperinsulinism/hyperammonemia syndrome. Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1219-25. doi: 10.1152/ajpendo.00028.2010. Epub 2010 Mar 23.
- Kelly A, Ng D, Ferry RJ Jr, Grimberg A, Koo-McCoy S, Thornton PS, Stanley CA. Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome. J Clin Endocrinol Metab. 2001 Aug;86(8):3724-8. doi: 10.1210/jcem.86.8.7755.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-018039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperinsulinism-Hyperammonemia Syndrome
-
Elizabeth A RosenfeldNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedHyperinsulinism-Hyperammonemia SyndromeUnited States
-
Children's Mercy Hospital Kansas CityWithdrawnHypoglycemia | Seizures | HyperammonemiaUnited States
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
Liminal BioSciences Ltd.TerminatedHyperammonemiaUnited Kingdom
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
University Hospital, GhentRecruitingHyperammonemic EncephalopathyBelgium
-
University of BrawijayaPT. Sahabat Lingkungan HidupEnrolling by invitation
-
University of Central LancashireNot yet recruitingCardiometabolic Syndrome
-
National University Hospital, SingaporeRecruitingThe Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN) (PICMAN)Cardiometabolic SyndromeSingapore
Clinical Trials on Vitamin E
-
Shiraz University of Medical SciencesCompletedRestless Legs Syndrome | Kidney Failure, ChronicIran, Islamic Republic of
-
National Institute of Diabetes and Digestive and...Completed
-
Hospital General Universitario ElcheCompleted
-
Aesculap AGRaylytic GmbH; B. Braun Medical FranceRecruitingArthritis, Rheumatoid | Osteoarthritis, Knee | Joint Instability | Intra-Articular Fractures | Genu Valgum or VarumFrance, Germany
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedChronic Arsenic PoisoningBangladesh
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBreast Cancer | FatigueUnited States
-
University of Health Sciences LahoreCompleted
-
Hospital General Universitario ElcheCompletedSurgical Site Infection
-
University Hospital, GenevaCompleted